FDA approves AstraZeneca’s oral SERD for breast cancer despite negative adcomm vote

AstraZeneca clinched an FDA accelerated approval for its oral SERD in certain breast cancer patients Friday, even after a negative vote from the agency’s advisory committee in April. Camizestrant, with the brand ...